Meta Ties Executive Pay to Aggressive Stock Price Targets in Major Retention Push 
AWS Bahrain Region Disrupted by Drone Activity Amid Middle East Conflict 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
Asian Currencies Weaken as Dollar Rebounds Amid Middle East Uncertainty and Japan Inflation Data 
Japan's Private Sector Growth Slows in March Amid Rising Costs and Middle East Uncertainty 
Middle East War Rattles Global Markets as Oil Tops $100 and Dollar Surges 
Citi Names Eric Farina and Rob Cascarino to Lead Global Infrastructure Financing Group 
Asian Markets Rally as Oil Prices Tumble and Middle East Peace Hopes Emerge 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
Australia-EU Free Trade Deal Signed After Years of Negotiations 
Japan Eyes Oil Futures Intervention to Stabilize Yen Amid Middle East Crisis 
Bank of Japan Eyes April Rate Hike Despite Inflation Dip, ING Says 
Gold Prices Climb as Middle East Ceasefire Talks Stir Market Optimism 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield 
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership 
Samsung Biologics is expanding its CMO or contract manufacturing organization business, and as part of its plans, it is constructing its very first overseas production plant in the United States.
On Monday, June 13, Samsung Biologics’ chief executive officer, John Rim, shared that they are considering several locations for the facility. He said that the strongest candidates for their CMO site are Texas, North Carolina, California, and Washington.
According to The Korea Herald, Samsung Biologics is looking into these places more because many of the major bio companies’ facilities are also operating in the mentioned US states. At this time, the company has not yet made any decision and carefully reviewing the areas to choose the best option.
“We are certainly expanding and the Plant 4 will begin partial operation in October, adding a 60,000-liter production capacity,” the Samsung Biologics’ CEO told the media during the press meeting for the 2022 BIO International Convention in San Diego, California. “By the second quarter of next year, it will have a 180,000-liter production capacity.”
While planning to build its first manufacturing plant abroad, Samsung Biologics has already set up its fourth factory in Songdo, Incheon, in South Korea. Once this facility starts operating at its full capacity, it is expected to boost production.
All in all, the four plants should produce 620,000 liters of products for around 30% of the global demand. It was said that Samsung Biologics’ Plant 4 currently has the biggest CMO production capacity in the world, with 256,000 liters of products in a single facility.
Rim revealed that they are also aiming to build the fifth and sixth factories in South Korea, and this is why they are buying more land in Incheon. The purchases were originally expected to be completed by the end of May, but the authorities could not sign the contract because the government officials who are in charge, which are the mayor and commissioner of the Incheon Free Economic Zone, have changed due to the local elections that was held earlier this month.
Finally, the Samsung Biologics chief said that they still plan to go ahead with the construction of Plant 5 and 6. However, they will not be monitoring the supply and demand trends to see if there is still a need to build more factories.
